Atopic Dermatitis in Adults: Is Dupilumab Right for You and How Does It Compare to Older Treatments?

Research-informed explainer — last updated April 12, 2026

Dupilumab, which blocks the IL-4 and IL-13 signaling pathways driving the itch-scratch cycle in atopic dermatitis, has transformed treatment for adults with moderate-to-severe disease — achieving clear or almost-clear skin in roughly half of patients in phase 3 trials. Newer JAK inhibitors and alternative biologics now give patients and physicians additional options when dupilumab causes conjunctivitis or fails to fully control symptoms.

This article draws on research from five dermatologists with extensive atopic dermatitis expertise. Dr. Timothy Berger, Clinical Professor of Dermatology at UCSF, co-authored three successive American Academy of Dermatology guidelines for atopic dermatitis management (1,230, 1,176, and 861 citations respectively) — the clinical framework that defines when systemic therapy is warranted. Dr. Peter Lio of Northwestern contributed the head-to-head upadacitinib vs. dupilumab trial (460 citations, JAMA Dermatology, 2021), providing direct comparison data between JAK inhibitors and biologic therapy. Dr. Andrew Alexis, Professor and Vice-Chair at Weill Cornell Medicine, contributed research on how AD presents and behaves differently in patients with skin of color (344 citations), and the ECZTRA 3 trial of tralokinumab with topical corticosteroids (307 citations). Dr. Kevin Cooper of UH Cleveland Medical Center established the Th2 immunological framework underpinning modern AD therapy through foundational pathogenesis work. Dr. John Browning of UT Health San Antonio co-authored the first phase 3 trial of dupilumab in infants and toddlers (244 citations, The Lancet, 2022).

What drives atopic dermatitis

Atopic dermatitis is not a simple allergy — it is a complex immune-mediated inflammatory disease of the skin barrier. Cooper's 1994 Journal of Investigative Dermatology paper (353 citations) established that AD is characterized by a Th2-skewed immune response, with overproduction of IL-4 and IL-13 cytokines. These interleukins drive itch, weaken the skin barrier, and promote IgE-mediated sensitization to environmental allergens.

Berger's 2013 and 2014 AAD guidelines define moderate-to-severe AD as disease that is not controlled by topical corticosteroids and emollients, covers more than 10% of body surface area, or substantially impairs quality of life. These criteria remain the threshold for considering systemic therapy.

Alexis's 2018 Experimental Dermatology review highlighted a clinically important nuance: AD in patients with darker skin types often presents with follicular accentuation, lichenification, and post-inflammatory hyperpigmentation rather than the classic erythema pattern described in lighter-skinned populations — meaning diagnosis can be delayed and appropriate systemic treatment started later.

The treatment ladder before dupilumab

The standard step-up approach before biologics includes:

• Emollients and moisturizers: The foundation of care at every step; repair the skin barrier
• Topical corticosteroids: First-line for mild-to-moderate flares; long-term use risks skin atrophy
• Topical calcineurin inhibitors (tacrolimus, pimecrolimus): Steroid-sparing; useful for sensitive areas like the face
• Topical PDE4 inhibitors (crisaborole): Approved for mild-to-moderate disease
• Phototherapy: Narrowband UVB; effective but requires 2–3 sessions per week
• Cyclosporine, methotrexate, azathioprine: Conventional systemic immunosuppressants; effective but carry organ toxicity risks with long-term use

What dupilumab is and how it works

Dupilumab (Dupixent) is a fully human monoclonal antibody that blocks the shared receptor subunit for IL-4 and IL-13. By blocking both cytokines simultaneously, it interrupts the central inflammatory driver of AD without broadly suppressing immunity.

In adult phase 3 SOLO trials, dupilumab 300 mg every two weeks achieved IGA 0/1 (clear or almost clear skin) in approximately 38% of patients and EASI-75 (75% reduction in disease extent) in 51% — compared with 10% and 15% for placebo. Response typically improves over the first 16 weeks of treatment.

Dupilumab is FDA-approved for adults, adolescents, children 6 years and older, and now infants and toddlers as young as 6 months. Browning co-authored the 2022 Lancet phase 3 trial (244 citations) showing that dupilumab was effective and well-tolerated in children aged 6 months to under 6 years — an important extension of the evidence base to the youngest patients.

How dupilumab compares to other systemic options

Lio co-authored the 2021 JAMA Dermatology head-to-head trial (460 citations) directly comparing upadacitinib 30 mg and 15 mg to dupilumab 300 mg. At 16 weeks, upadacitinib 30 mg achieved significantly higher IGA 0/1 rates (48% vs. 36%) and EASI-75 rates (71% vs. 61%). However, upadacitinib carries a class-wide boxed warning for JAK inhibitors regarding serious infections, thrombosis, cardiovascular events, and malignancy — risks that are reflected in labeling and require patient counseling.

Alexis contributed to the ECZTRA 3 trial of tralokinumab (307 citations, British Journal of Dermatology), which showed that tralokinumab 300 mg every two weeks combined with topical corticosteroids achieved IGA 0/1 in 43% of patients. Tralokinumab blocks IL-13 only — not IL-4 — which may explain lower rates of conjunctivitis compared to dupilumab.

Dupilumab and conjunctivitis

Conjunctivitis (eye redness, irritation, discharge) occurs in approximately 8–10% of dupilumab-treated patients — higher than with IL-13-only blockers. This side effect is thought to result from IL-4 pathway blockade in the conjunctival mucosa. For most patients, it is manageable with preservative-free artificial tears, topical antihistamine eye drops, or occasional short courses of topical corticosteroid eye drops. Severe cases may require switching to tralokinumab.

Who is a candidate for dupilumab vs. alternatives

Dupilumab is generally preferred if:

• You want a biologic with the longest safety track record (approved 2017)
• You also have comorbid asthma or chronic rhinosinusitis with nasal polyps (dupilumab is approved for both)
• You are pregnant or may become pregnant (biologic preferred over JAK inhibitor)
• You want every-other-week self-injection at home

Consider a JAK inhibitor if:

• Maximum speed of response matters and you have no contraindications to the class
• You prefer a daily oral pill over injection
• Prior dupilumab was ineffective or poorly tolerated

Consider tralokinumab if:

• Dupilumab caused significant conjunctivitis
• You want an approved biologic with a distinct mechanism

Questions to ask your doctor

• Have I tried maximally optimized topical therapy and phototherapy before considering a biologic or JAK inhibitor?
• Does my medical history — cardiovascular disease, history of clots, active infections — make a JAK inhibitor higher risk for me?
• I also have asthma; could dupilumab address both conditions?
• If dupilumab causes eye irritation, is that a reason to stop it or is it manageable?
• Are there biosimilars or patient assistance programs for dupilumab given the cost?
• How long should I give a treatment before deciding it is not working?

The bottom line

Dupilumab has become the default systemic treatment for adults with moderate-to-severe atopic dermatitis who have failed topical therapy, offering meaningful skin clearance with an acceptable safety profile and no organ toxicity monitoring. JAK inhibitors offer faster and numerically higher clearance rates but carry a class-wide boxed warning that requires careful patient selection. Newer IL-13-specific biologics like tralokinumab provide an alternative for patients who develop dupilumab-related conjunctivitis. The expanding treatment landscape means almost all adults with persistent AD can now achieve substantially improved quality of life with an appropriately chosen systemic therapy.